How Semaglutide Moves Through Your Body: A Complete Pharmacokinetics Review | Research

The takeaway

A systematic review of 17 studies maps out semaglutide's pharmacokinetic profile for both subcutaneous and oral forms, finding predictable absorption with a long half-life enabling once-weekly injection and minimal drug interactions.

17 studies reviewed
Comprehensive pharmacokinetic data compiled for both subcutaneous and oral semaglutide across healthy and diseased populations

What the researchers found

Semaglutide has a predictable pharmacokinetic profile with a long half-life supporting once-weekly subcutaneous dosing. Oral semaglutide exposure is affected by food and dosing conditions, but neither form requires dose adjustment for renal or hepatic impairment.

Why it matters

Understanding semaglutide's pharmacokinetics helps clinicians optimize dosing, counsel patients on proper oral administration, and predict how the drug will behave in patients with different body weights or organ impairment.

The numbers in context

Subcutaneous: ~1 week half-life, 1-3 day Tmax. Oral: ~1% bioavailability, requires fasting. Population PK parameters across multiple subgroups.

How the study worked

Systematic review of 17 studies from PubMed and Embase reporting semaglutide pharmacokinetic parameters (AUC, Cmax, time to Cmax, half-life, and clearance) in healthy and diseased populations.

Who was studied

Healthy and diseased human populations across PK studies

What this study cannot tell us

Limited data on the effect of body weight on exposure. Pharmacokinetic studies may not capture real-world variability in absorption. Oral semaglutide data is more limited than subcutaneous. Does not address pharmacokinetics of higher doses used for weight management.

How to read the evidence

Strong evidence — systematic review synthesizing 17 pharmacokinetic studies, providing a comprehensive picture of semaglutide drug behavior.

When this study was published

Published in 2024, incorporating the most current pharmacokinetic data available for semaglutide.

The bigger picture

As semaglutide becomes one of the most prescribed medications globally, comprehensive pharmacokinetic data is essential for developing generic formulations, predicting drug interactions, and optimizing dosing strategies for diverse patient populations.

Questions still open

How does body composition (lean mass vs. fat mass) specifically affect semaglutide exposure?
Do the pharmacokinetic profiles differ meaningfully in patients with very high BMI versus normal weight?
Could alternative oral formulations overcome the food and water restrictions of current oral semaglutide?

Common questions

Why does oral semaglutide need to be taken on an empty stomach?

Food significantly reduces the absorption of oral semaglutide. The review confirmed that eating before or shortly after taking the tablet decreases drug exposure, which is why patients are advised to take it at least 30 minutes before their first meal with no more than 4 ounces of water.

Does semaglutide interact with other medications?

The review found limited drug-drug interactions with semaglutide. While it can slightly delay gastric emptying (which could theoretically affect absorption of other oral drugs), clinically significant interactions are rare and no routine dose adjustments are needed for common co-medications.

Read the original research

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Drug design, development and therapy, 18, 2555-2570

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Xi-Ding; Yang, Yong-Yu. (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review.. Drug design, development and therapy, 18, 2555-2570. https://doi.org/10.2147/DDDT.S470826